-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KmklO9cQzAYHNVJyKGhWN+sldplct7Xjdt60plRCp6Gihyq8M8XXUYNXophKxq5m cBmkYnSIhauX+qQd3JWv8Q== 0001367982-07-000064.txt : 20070202 0001367982-07-000064.hdr.sgml : 20070202 20070202114220 ACCESSION NUMBER: 0001367982-07-000064 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070131 FILED AS OF DATE: 20070202 DATE AS OF CHANGE: 20070202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROWLAND LLOYD A CENTRAL INDEX KEY: 0001236395 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19700 FILM NUMBER: 07575104 BUSINESS ADDRESS: BUSINESS PHONE: 8585522200 MAIL ADDRESS: STREET 1: AMYLIN PHARMACEUTICALS INC STREET 2: 9360 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0202 4 2007-01-31 0 0000881464 AMYLIN PHARMACEUTICALS INC AMLN 0001236395 ROWLAND LLOYD A 9360 TOWNE CENTRE DR SAN DIEGO CA 92121 0 1 0 0 VP Legal & General Counsel Common Stock 2007-01-31 4 A 0 416 36.07 A 23237 D Common Stock 2007-02-01 4 M 0 2000 11.95 A 25237 D Common Stock 2007-02-01 4 S 0 2000 38.92 D 23237 D Non-Qualified Stock Option (right to buy) 11.95 2007-02-01 4 M 0 2000 0 D 2012-08-02 Common Stock 2000 25 D Represents shares acquired pursuant to the Company's 401(k) plan. This sale was affected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. One-fourth (1/4) of this option grant vested on Aug. 2, 2003 with the remainder of the grant vesting monthly over the next three years becoming fully-vested four years from the date of grant. Lloyd A. Rowland 2007-02-01 -----END PRIVACY-ENHANCED MESSAGE-----